131 results
Page 3 of 7
425
EX-99.1
xwislku0
29 Mar 21
Business combination disclosure
7:27am
8-K
EX-99.1
f05i17x3fodxfth1lx
24 Sep 20
Millendo Therapeutics Announces Initiation of First-in-Human Clinical Trial of MLE-301, a Selective NK3R Antagonist
8:33am
8-K
wwy4ckrs
6 Apr 20
Cost Associated with Exit or Disposal Activities
7:16am
8-K
EX-99.1
d9jds4bwlti04ujjn0g
6 Apr 20
Cost Associated with Exit or Disposal Activities
7:16am
UPLOAD
oyy66z3
12 Apr 19
Letter from SEC
12:00am
8-K
EX-99.1
fgog3neapcyd 346to
13 Dec 18
Millendo Therapeutics Announces Successful Merger Completion
4:08pm
8-K
EX-10.4
il3dmtyrb45 dan
6 Dec 18
Entry into a Material Definitive Agreement
6:18am
8-K
EX-10.2
rig arvjp5cr
6 Dec 18
Entry into a Material Definitive Agreement
6:18am
8-K
EX-10.3
d8a 93s3lor0
6 Dec 18
Entry into a Material Definitive Agreement
6:18am
UPLOAD
wxb0 rq4k
20 Nov 18
Letter from SEC
12:00am